Brief: Aprea Therapeutics Announces Removal Of FDA Clinical Hold On Eprenetapopt In Lymphoid Malignancies
09/12/2021 13:08
Dec 9 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA THERAPEUTICS ANNOUNCES REMOVAL OF FDA CLINICAL HOLD
ON
EPRENETAPOPT IN LYMPHOID MALIGNANCIES
Source text for Eikon: ID:nGNX4T6Vf5
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing